BACKGROUND: Cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS) may be driven by aberrant T-cell responses against cryptococci. We investigated this in human immunodeficiency virus (HIV)-infected patients with treated cryptococcal meningitis (CM) commencing combination antiretroviral therapy (cART). METHODS: Mitogen- and cryptococcal mannoprotein (CMP)-activated (CD25+CD134+) CD4+ T cells and -induced production of interferon-gamma (IFN-γ), IL-10, and CXCL10 were assessed in whole blood cultures in a prospective study of 106 HIV-CM coinfected patients. RESULTS: Patients with paradoxical C-IRIS (n = 27), compared with patients with no neurological deterioration (no ND; n = 63), had lower CMP-induced IFN-γ production in 24-hour cultures pre-cART and 4 weeks post-cART (P = .0437 and .0257, respectively) and lower CMP-activated CD4+ T-cell counts pre-cART (P = .0178). Patients surviving to 24 weeks had higher proportions of mitogen-activated CD4+ T cells and higher CMP-induced CXCL10 and IL-10 production in 24-hour cultures pre-cART than patients not surviving (P = .0053, .0436 and .0319, respectively). C-IRIS was not associated with higher CMP-specific T-cell responses before or during cART. CONCLUSION: Greater preservation of T-cell function and higher CMP-induced IL-10 and CXCL10 production before cART are associated with improved survival while on cART. Lower CMP-induced IFN-γ production pre-cART, but not higher CMP-specific T-cell responses after cART, were risk factors for C-IRIS.
BACKGROUND:Cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS) may be driven by aberrant T-cell responses against cryptococci. We investigated this in human immunodeficiency virus (HIV)-infectedpatients with treated cryptococcal meningitis (CM) commencing combination antiretroviral therapy (cART). METHODS: Mitogen- and cryptococcal mannoprotein (CMP)-activated (CD25+CD134+) CD4+ T cells and -induced production of interferon-gamma (IFN-γ), IL-10, and CXCL10 were assessed in whole blood cultures in a prospective study of 106 HIV-CM coinfectedpatients. RESULTS:Patients with paradoxical C-IRIS (n = 27), compared with patients with no neurological deterioration (no ND; n = 63), had lower CMP-induced IFN-γ production in 24-hour cultures pre-cART and 4 weeks post-cART (P = .0437 and .0257, respectively) and lower CMP-activated CD4+ T-cell counts pre-cART (P = .0178). Patients surviving to 24 weeks had higher proportions of mitogen-activated CD4+ T cells and higher CMP-induced CXCL10 and IL-10 production in 24-hour cultures pre-cART than patients not surviving (P = .0053, .0436 and .0319, respectively). C-IRIS was not associated with higher CMP-specific T-cell responses before or during cART. CONCLUSION: Greater preservation of T-cell function and higher CMP-induced IL-10 and CXCL10 production before cART are associated with improved survival while on cART. Lower CMP-induced IFN-γ production pre-cART, but not higher CMP-specific T-cell responses after cART, were risk factors for C-IRIS.
Authors: W Chaka; A F Verheul; V V Vaishnav; R Cherniak; J Scharringa; J Verhoef; H Snippe; I M Hoepelman Journal: Infect Immun Date: 1997-01 Impact factor: 3.441
Authors: Christina C Chang; Afton A Dorasamy; Bernadett I Gosnell; Julian H Elliott; Tim Spelman; Saleha Omarjee; Vivek Naranbhai; Yacoob Coovadia; Thumbi Ndung'u; Mohamed-Yunus S Moosa; Sharon R Lewin; Martyn A French Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Peter G Pappas; Beatriz Bustamante; Eduardo Ticona; Richard J Hamill; Philip C Johnson; Annette Reboli; Judith Aberg; Rodrigo Hasbun; Henry H Hsu Journal: J Infect Dis Date: 2004-05-24 Impact factor: 5.226
Authors: Peter R Williamson; Joseph N Jarvis; Anil A Panackal; Matthew C Fisher; Síle F Molloy; Angela Loyse; Thomas S Harrison Journal: Nat Rev Neurol Date: 2016-11-25 Impact factor: 42.937
Authors: Christina C Chang; Saleha Omarjee; Andrew Lim; Tim Spelman; Bernadett I Gosnell; William H Carr; Julian H Elliott; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Martyn A French; Sharon R Lewin Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Ngomu Akeem Akilimali; Daniel M Muema; Charles Specht; Christina C Chang; Mahomed-Yunus S Moosa; Stuart M Levitz; Sharon R Lewin; Martyn A French; Thumbi Ndungʼu Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988